Table 2.
Exposure to brentuximab vedotin
| Total | HL | sALCL | |
|---|---|---|---|
| (N = 284)a | (n = 182) | (n = 101) | |
| Initial dose, mg/kg | |||
| < 1.2 | 7 (2.5) | 4 (2.2) | 3 (3.0) |
| 1.2 | 17 (6.0) | 9 (4.9) | 8 (7.9) |
| > 1.2– < 1.8 | 12 (4.2) | 9 (4.9) | 3 (3.0) |
| 1.8 | 247 (87.0) | 159 (87.4) | 87 (86.1) |
| > 1.8 | 1 (0.4) | 1 (0.5) | 0 |
| Mean dose per cycle is 1.8 mg/kg | 214 (75.4) | 141 (77.5) | 72 (71.3) |
| Median number of cycles received (range) | 5.0 (1–17) | 5.5 (1–16) | 4.0 (1–17) |
| Reasons for study drug discontinuation (cumulative) | |||
| Treatment objective was achieved | 60 (21.1) | 35 (19.2) | 25 (24.8) |
| AE | 63 (22.2) | 42 (23.1) | 21 (20.8) |
| Discontinuation of clinic visits | 1 (0.4) | 1 (0.5) | 0 |
| Transfer to another clinic | 9 (3.2) | 5 (2.7) | 4 (4.0) |
| Lack of efficacy | 115 (40.5) | 74 (40.7) | 40 (39.6) |
| Others | 53 (18.7) | 34 (18.7) | 18 (17.8) |
| Received HSCT after BV treatment | 56 (19.7) | 36 (19.8) | 20 (19.8) |
| Autologous | 35 (62.5) | 26 (72.2) | 9 (45.0) |
| Allogenic | 21 (37.5) | 10 (27.8) | 11 (55.0) |
| Received other combination therapies | 31 (10.9) | 18 (9.9) | 13 (12.9) |
aIncludes one patient with diffuse large B-cell lymphoma
Number of cases (%) are shown unless indicated otherwise
AE adverse event, BV brentuximab vedotin, HL Hodgkin lymphoma, HSCT hematopoietic stem cell transplant, sALCL systemic anaplastic large cell lymphoma